Business
SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data-driven treatment planning for advanced ovarian
About this update from Sophia Genetics Sa
[{"type":"text","content":"With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data-driven treatment planning for advanced ovarian cancer \nBOSTON and ROLLE, Switzerland, Sept. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, is helping excel the use of precision medicine to treat advanced ovarian cancer. The company today announced that the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", an oncology center in Italy, is using the SOPHiA DDM™ Platform to power a new genomic test that will be used to aid physicians in developing personalized treatment plans for those with advanced ovarian cancer.\n\n \n \n \n \n \n \n\n \nIRST, which is recognized for its excellence as a scientific hospital and treatment institute for advanced oncology in the Emilia-Romagna Region, is one of only three \"Hub Centers\" authorized by the Region to perform this new test. With use of the SOPHiA DDM™ Platform, the test will help identify patients with a homologous recombination deficiency (HRD), which is caused by a cell's impaired ability to repair DNA double-stranded breaks. Identifying HRD is extremely important for oncologists, as it can be used as a predictive biomarker for therapy response,1 and roughly half of the women affected by advanced ovarian cancer have HRD2.\n\"The newly available HRD test will help our oncologists make data-based treatment plans that can potentially save the lives of patients who are diagnosed with, and treated for, advanced ovarian cancer at IRST,\" said Daniele Calistri, PhD., Head of Advanced and Predictive Molecular Diagnostics Area - IRST \"Dino Amadori\" IRCCS Bioscience Laboratory. \"The key to success with the test is the ability to quickly turn data into insights, so that our physicians can make the appropriate treatment plans; that is where the SOPHiA DDM™ Platform comes in. With the SOPHiA GENETICS technology, our team can move fast with the confidence that they are making strong decisions rooted in patient data.\"\nThe new test is performed on cancerous tissue using next-generation sequencing (NGS) and produces an extensive amount of data. The SOPHiA DDM™ Platform is a NGS-based application, that uses artificial intelligence (AI) and machine learning to analyze and interpret raw NGS ...